enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. US FDA staff questions confirmatory trial data for Intercept ...

   www.aol.com/news/fda-staff-raises-efficacy...

   Intercept said only one case of liver transplant was possibly related to the drug. The company, which holds the drug's U.S. commercial rights, was acquired by Italy's Alfasigma for nearly $800 ...

3. Is Intercept Pharma's Updated Late-Stage NASH Data A ... - AOL

   www.aol.com/news/intercept-pharmas-updated-stage...

   Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced additional positive data from its pivotal Phase 3 REGENERATE trial Wednesday. The trial is evaluating Intercept's obeticholic acid, or OCA ...

4. US FDA declines to approve Intercept's fatty liver disease drug

   www.aol.com/news/us-fda-declines-approve...

   The rejection marks Intercept's second failed attempt at securing approval for the drug to treat patients with non-alcoholic steatohepatitis (NASH) - a liver disease that affects 5% of U.S. adults ...

5. Intercept to go back to FDA with its NASH treatment application

   www.aol.com/news/intercept-resubmit-nash...

   Intercept said its treatment led to statistically significant reduction in fibrosis in patients with NASH after 18 months compared to the placebo, based on interim analysis.

6. Intercept Pharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/Intercept_Pharmaceuticals

   Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary ...

7. Intercept Shares Jump After Reissuing Annual Guidance - AOL

   www.aol.com/news/intercept-shares-jump-reissuing...

   Intercept Pharmaceuticals Inc (NASDAQ: ICPT) completed the sale of its international business for $405 million in upfront consideration. The company held a pre-submission meeting with FDA in July ...

8. Analysts Expect Clarity Imminent On Intercept's NASH Story - AOL

   www.aol.com/news/analysts-expect-clarity...

   RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ: ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid (OCA ...

9. Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat

   www.aol.com/news/intercepts-icpt-q2-loss...

   Intercept (ICPT) posts a narrower loss in the second quarter and sales beat estimates.